On this page
Quick Reference
Overview and Recommendations
Background
- •Alcohol Withdrawal Syndrome (AWS) is a clinical entity defined by autonomic hyperactivity and neuropsychiatric distress following the abrupt cessation of chronic ethanol intake, affecting approximately 5.8% of all hospitalizations.
- •The neurobiological paradigm involves a functional decoupling of the GABA and NMDA systems; chronic alcohol exposure leads to GABA-A receptor downregulation and NMDA receptor upregulation, resulting in unopposed CNS hyperexcitation when alcohol is removed.
- •Clinical severity ranges from mild tremors and anxiety to severe complications, including withdrawal seizures (typically 6-48 hours post-cessation) and delirium tremens (typically 48-96 hours post-cessation), which carries a high mortality rate if untreated.
- •Risk stratification is the cornerstone of modern management, as a history of delirium tremens (LR 2.9) or a score ≥ 4 (LR 174) are potent predictors of progression to severe alcohol withdrawal syndrome (SAWS).
- •The 'autonomic storm' characteristic of severe AWS is driven by a massive noradrenergic surge from the locus coeruleus, manifesting as tachycardia, hypertension, diaphoresis, and hyperthermia.
Evaluation
- •Suspect AWS in any patient with a history of heavy alcohol use presenting with unexplained tremors, anxiety, diaphoresis, or gastrointestinal distress within 6-24 hours of their last drink.
- •Ask specifically about a history of withdrawal seizures or delirium tremens, as these are the strongest predictors of future complicated withdrawal episodes.
- •Examine for hallmark signs of autonomic hyperactivity, including a fine-to-moderate kinetic tremor of the hands, tachycardia, and systolic blood pressure ≥ 140 mm Hg.
- •Order a complete blood count (CBC) to assess for thrombocytopenia (OR 1.61 for AWS risk) and a comprehensive metabolic panel (CMP) to evaluate liver function (AST ≥ 40 U/L) and electrolyte derangements.
- •Utilize the (Prediction of Alcohol Withdrawal Severity Scale) upon admission; a score ≥ 4 indicates a high risk for severe withdrawal and should trigger aggressive prophylaxis.
- •Implement serial (Clinical Institute Withdrawal Assessment for Alcohol-Revised) scoring every 1-4 hours to objectively monitor symptom progression and guide therapy.
- •Rule out organic mimics in patients with altered mental status or seizures, including , , hypoglycemia, or intracranial hemorrhage.
- •Consider a CT head or lumbar puncture if the patient presents with focal neurological deficits, high fever, or if seizures occur outside the typical 6-48 hour window.
- •Assess for comorbid chronic pain, as withdrawal-induced hyperalgesia is a common driver of distress and increased relapse risk.
Management
- •Initiate symptom-triggered therapy rather than fixed-dose regimens to reduce total medication requirements and hospital length of stay.
- •Administer as the first-line standard of care; for CIWA-Ar scores ≥ 8-10, give 2 mg IV/PO or 10 mg IV/PO every 1-2 hours until symptoms stabilize.
- •Use (2 mg) or in patients with known or suspected hepatic impairment, as these do not require oxidative metabolism by the liver.
- •Add as an adjunct for moderate-to-severe AWS; a single dose of 10 mg/kg IV can significantly reduce ICU admission rates and the need for mechanical ventilation.
- •Consider 300-600 mg TID as a benzodiazepine-sparing agent for mild-to-moderate withdrawal or as part of a step-down protocol.
- •Monitor for refractory alcohol withdrawal (RAW); if symptoms persist despite high-dose benzodiazepines (e.g., > 50 mg diazepam in 1 hour), escalate to a or infusion in an ICU setting.
- •Avoid using antipsychotics like as monotherapy, as they lower the seizure threshold; they should only be used as adjuncts for severe agitation alongside benzodiazepines.
- •Correct electrolyte abnormalities aggressively, particularly hypokalemia and hypomagnesemia, to prevent QTc prolongation and .
- •Administer thiamine 100-500 mg IV/IM daily to all patients at risk to prevent , ideally before any glucose-containing fluids.
- •Refer patients to addiction medicine or long-term rehabilitation services once acute stabilization is achieved to address the underlying .
Board Review — High Yield
- •Delirium Tremens, Typically occurs 48-96 hours after the last drink; characterized by autonomic instability and clouded sensorium.
- •Withdrawal Seizures, Usually generalized tonic-clonic, occurring 6-48 hours post-cessation; often occur before the onset of DTs.
- •PAWSS Score, A score of 4 or more has a likelihood ratio of 174 for predicting severe alcohol withdrawal syndrome.
- •GABA vs NMDA, Withdrawal is caused by decreased GABAergic inhibition and increased glutamatergic (NMDA) excitation.
- •Wernicke Encephalopathy Triad, Encephalopathy, oculomotor dysfunction, and ataxia; treat with high-dose thiamine.
- •Alcoholic Hallucinosis, Occurs within 12-24 hours; characterized by vivid hallucinations with a clear sensorium (unlike DTs).
- •Kindling Effect, Successive withdrawal episodes tend to increase in severity due to permanent neurochemical changes.
- •Benzodiazepine Selection, Use 'LOT' (Lorazepam, Oxazepam, Temazepam) in liver failure as they bypass phase I metabolism.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸AWS affects 5.8% of general hospitalizations and 19% of psychiatric settings [3].
- ▸HAWP scores predict length of stay and total [[lorazepam]] requirements [1].
Alcohol withdrawal syndrome (AWS) affects 5.8% of hospitalizations [3]B2c. Diagnosis requires two or more clinical signs following alcohol cessation [4]B3b. Severity is quantified using the CIWA-Ar or the Highland Alcohol Withdrawal Protocol (HAWP); higher HAWP scores correlate with a 0.45-day increase in hospital stay per point [1]B3b. Complicated AWS involves seizures (13.1%) or delirium tremens (DTs) [1]B3b. Resistant Alcohol Withdrawal (RAW) fails to respond to standard , often requiring mechanical ventilation (81.9%) [9]B3b.
| Classification | Key Feature | Clinical Significance |
|---|---|---|
| Mild/Moderate | Autonomic hyperactivity | Symptom-triggered [5]B2c |
| Severe | Seizures, DTs, intubation | High complication rates [1]B3b |
| Resistant (RAW) | BZD failure | Median ICU stay 9.0 days [9]B3b |
Pearl: AWS can develop in patients with a negative blood alcohol level on admission; an AUDIT-PC score ≥4 is a highly sensitive (91.0%) predictor of subsequent withdrawal risk [2]B3b[8]B3b.
| Feature | Statistic | Source |
|---|---|---|
| National Inpatient Prevalence | 5.8% (95% CI 5.2%-6.4%) | [3]B2c |
| Seizure Rate (Complicated AWS) | 13.1% | [1]B3b |
| Intubation Rate (Complicated AWS) | 12.9% | [1]B3b |
| AUDIT-PC Sensitivity (Score ≥4) | 91.0% | [8]B3b |
| Median ICU Stay (Resistant AWS) | 9.0 days | [9]B3b |
Neurobiology and Pathophysiology
- ▸GABA hypofunction and NMDA hyperactivity drive the core withdrawal symptoms [22].
- ▸Noradrenergic surge from the locus coeruleus causes the 'autonomic storm' [25].
Chronic alcohol exposure causes homeostatic neuroadaptation: downregulation of inhibitory GABAergic pathways and upregulation of excitatory glutamatergic systems [26]D5. Withdrawal removes ethanol's effects, leaving these adaptations unopposed [24]D5. Primary mechanisms include GABA-A receptor hypofunction and NMDA receptor hyperactivity, leading to neurotoxicity and agitation [22]D5[17]A1b. Secondary pathways involve a massive noradrenergic surge from the locus coeruleus, causing tachycardia and diaphoresis [25]D5. Alpha-2 agonists like target this surge [25]D5. Post-acute withdrawal (PAWS) can persist for 4-6 months, involving altered cortisol and serotonin levels [16]D5.
Pearl: The clinical severity of withdrawal is a direct reflection of the degree of GABA-receptor downregulation and NMDA-receptor upregulation; this explains why GABA-agonists like benzodiazepines are the mechanistic cornerstone of treatment [22]D5.
| System | Acute Ethanol Effect | Chronic Adaptation | Withdrawal State | Clinical Manifestation |
|---|---|---|---|---|
| GABA | Agonism (Inhibition) | Receptor Downregulation | Severe Hypofunction | Anxiety, Seizures, Tremor |
| Glutamate | NMDA Antagonism | Receptor Upregulation | Hyper-excitability | Delirium, Neurotoxicity |
| Norepinephrine | Decreased Release | Increased Synthesis | Massive Surge | Tachycardia, Hypertension |
| Dopamine | Increased Release | Decreased Baseline | Hypodopaminergic | Dysphoria, Cravings |
Epidemiology, Etiology and Risk Factors
- ▸PAWSS score ≥4 is the most robust predictor of severe withdrawal (LR 174) [27].
- ▸AWS in surgical settings increases the risk of postoperative sepsis and respiratory failure [39].
AWS incidence is 0.5% in general surgery but 32% in alcohol-associated hepatitis [39]B2c[30]B2b. A history of delirium tremens (DT) is a potent predictor (LR 2.9) [27]A1a. Baseline systolic BP ≥140 mm Hg also increases risk (LR 1.7) [27]A1a. In trauma, risk factors include age ≥45, heavy drinking, and Injury Severity Score ≥15 [31]B2b. Surgical patients with AWS face higher risks for respiratory failure (AOR 2.44) and sepsis (AOR 1.61) [39]B2c.
| Factor | Association | Evidence |
|---|---|---|
| History of DT | LR 2.9 for SAWS | 1a [27]A1a |
| PAWSS Score ≥4 | LR 174 for SAWS | 1a [27]A1a |
| Low Platelets | OR 1.61 for AWS | 2b [30]B2b |
Pearl: A history of delirium tremens is the strongest individual predictor of severe withdrawal (LR 2.9), but the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) provides superior stratification, with a score of 4 or more yielding an LR of 174 [27]A1a.
| Predictor | Likelihood Ratio (LR) | 95% CI |
|---|---|---|
| History of Delirium Tremens | 2.9 | 1.7-5.2 |
| Systolic BP ≥140 mm Hg | 1.7 | 1.3-2.3 |
| PAWSS Score ≥4 | 174 | 43-696 |
| PAWSS Score ≤3 | 0.07 | 0.02-0.26 |
Clinical Presentation
- ▸Withdrawal seizures usually occur within 6-48 hours but can be delayed by metabolic factors [43, 34].
- ▸Autonomic instability and hyperthermia are red flags for impending delirium tremens.
Symptoms typically emerge 6-24 hours after the last drink [34]C4. Early signs include autonomic hyperactivity (diaphoresis, tachycardia, ), kinetic tremor, and anxiety [49]A1b[29]D5. Neurological findings may include hyperreflexia and tactile hallucinations [49]A1b. Seizures are typically generalized tonic-clonic, occurring 6-48 hours post-cessation [43]A1a.
| Variant | Key Features | Context |
|---|---|---|
| Uncomplicated | Tremor, anxiety, arousal | Most common [49]A1b |
| Complicated | Seizures or DTs | High-risk history [50]B2a |
| Protracted | Craving, anhedonia | Lasts weeks/months [47]A1a |
| Pellagra | Dermatitis, diarrhea, dementia | Rare; needs niacin [51]C4 |
Pearl: Do not rely solely on the 48-hour window for seizure risk; metabolic alterations, such as prior gastric bypass, can delay the onset of life-threatening withdrawal symptoms to 70 hours or beyond [34]C4.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Uncomplicated AWS | Mild-to-moderate tremors, anxiety, and autonomic arousal without seizures or delirium. | Most common presentation [49]A1b. |
| Complicated AWS | Presence of withdrawal seizures or progression to delirium tremens. | Higher risk in those with prior severe episodes [50]B2a. |
| Protracted Withdrawal | Persistent craving, sleep disorders, and anhedonia lasting weeks to months. | Common; craving scores (OCDS) may remain elevated (mean 9.7) at 3 months [47]A1a. |
| Alcoholic Pellagra | Dermatitis, diarrhea, and dementia (3D spectrum) alongside AWS. | Rare; often lacks the full triad; requires high suspicion [51]C4. |
Diagnosis and Workup
- ▸Symptom-triggered therapy guided by CIWA-Ar reduces treatment duration by ~60 hours [54].
- ▸Thrombocytopenia and baseline SBP ≥140 are key laboratory/clinical markers of risk [30, 27].
Diagnosis requires ≥2 symptoms (e.g., tremor, tachycardia, insomnia) after reducing intake [56]A1c. Workup must rule out mimics like , , or [48]B2b[53]A1c. CIWA-Ar is the gold standard for monitoring severity [55]A1a. PAWSS score ≥4 has a likelihood ratio (LR) of 174 for severe withdrawal [27]A1a.
| Mimic | Diagnostic Consideration |
|---|---|
| Infection | Seizures occur in 18% of AUD patients with [48]B2b |
| Metabolic | is common but routine supplementation is debated [41]A1a |
| Neurologic | Consider if ataxia or confusion present [53]A1c |
Pearl: A PAWSS score of 4 or more is the most robust predictor of severe withdrawal (LR 174), and its use should trigger aggressive prophylaxis or ICU-level monitoring [27]A1a.
| Finding | Statistic | Clinical Significance |
|---|---|---|
| PAWSS Score ≥4 | LR 174 | High risk for DTs or seizures |
| History of DTs | LR 2.9 | Strongest single historical predictor |
| Systolic BP ≥140 mmHg | LR 1.7 | Baseline autonomic hyperactivity |
| Previous AWS History | OR 2.09 | Increased risk of recurrence |
| Thrombocytopenia | OR 1.61 | Marker of chronic use/liver disease |
Severity, Course Specifiers and Risk Stratification
- ▸Wetterling scale scores >9 independently associate with increased in-hospital mortality [58].
- ▸AWS is an independent risk factor for requiring [[invasive mechanical ventilation]] in chest trauma [67].
Risk stratification determines monitoring intensity. PAWSS ≥4 (LR 174) necessitates aggressive prophylaxis [27]A1a. Baseline CIWA-Ar >8 often triggers adjuvant therapy [52]A1b. In patients with alcohol-associated hepatitis, AWS increases 28-day mortality (HR 2.31) and the need for mechanical ventilation (OR 2.49) [30]B2b.
| Risk Category | Predictors | Impact |
|---|---|---|
| Historical | Prior DTs or AWS | OR 2.09 for incident AWS [30]B2b |
| Physiological | SBP ≥140, Low Platelets | Higher SAWS likelihood [27]A1a[30]B2b |
| Injury | ISS ≥15, ICU admission | Hyperadrenergic states [31]B2b |
Pearl: A PAWSS score of 4 or more is the most robust clinical predictor of severe withdrawal, carrying a likelihood ratio of 174, and should trigger aggressive prophylaxis or high-intensity monitoring [27]A1a.
| Predictor | Metric | Significance |
|---|---|---|
| PAWSS Score ≥4 | LR 174 | High risk of SAWS [27]A1a |
| PAWSS Score ≤3 | LR 0.07 | Low risk of SAWS [27]A1a |
| History of Delirium Tremens | LR 2.9 | Increased likelihood of SAWS [27]A1a |
| Systolic BP ≥140 mm Hg | LR 1.7 | Increased likelihood of SAWS [27]A1a |
| Previous AWS History | OR 2.09 | Predictor of incident AWS in hepatitis [30]B2b |
Acute Management and Psychiatric Emergencies
- ▸Symptom-triggered BZD regimens are superior to fixed-dose for reducing treatment duration [77].
- ▸[[Phenobarbital]] is a reasonable adjunct but may not reduce ICU admissions compared to BZDs alone [73].
Stabilization focuses on GABAergic modulation. are first-line, typically symptom-triggered via CIWA-Ar [74]A1a[77]A1b. For moderate-to-severe AWS, SAEM -4 suggests adding [44]A1c. Adjuvant IV at 7.5 mg/kg is effective [79]A1b. (30-60 mg/day) reduces requirements [77]A1b. (2 g/day) can be used as a BZD-sparing agent [78]A1b.
Pearl: Use the PAWSS tool to identify high-risk patients; a score of 4 or more strongly predicts severe withdrawal, necessitating aggressive management with or adjunctive [27]A1a[44]A1c.
| Drug | Starting dose | Target / max dose | Key monitoring |
|---|---|---|---|
| 7.5 mg/kg IV (single dose) | Titrated to effect | Respiratory rate, sedation level | |
| 10 mg PO TID | 60 mg/day | Renal function, sedation | |
| 2 g/day | 2 g/day for 4 days | Visual fields (long-term), sedation | |
| Varies | Varies | Renal function (eGFR) |
Long-Term and Definitive Management
- ▸[[Phenobarbital]] (10 mg/kg) is a potent adjunct for BZD-refractory withdrawal [85].
- ▸Do NOT use [[dextromethorphan]] or [[oxytocin]] to reduce BZD requirements; trials show no efficacy [17, 81].
Definitive care addresses refractory symptoms. Loading BZD protocols may clear symptoms faster than symptom-triggered (69.6% vs 41.7% at 72h) [82]A1b. Adjunctive (10 mg/kg IV) reduces ICU admissions from 25% to 8% [85]A1b. reduces 12-hour BZD needs but causes bradycardia in 35% of patients [87]B3b. is for ICU delirium but must be paired with BZDs to avoid lowering the seizure threshold [89]D5.
| Drug | Dose | Key Monitoring |
|---|---|---|
| 10 mg/kg IV | Respiratory rate, sedation | |
| 2 mg (1 mg rescue) | CIWA-Ar score | |
| Adjunctive | Heart rate (bradycardia) | |
| 426.6 mg/d | Serum magnesium |
Pearl: Phenobarbital (10 mg/kg IV) significantly reduces ICU admission rates when added to BZD protocols, but routine magnesium and oxytocin do not improve clinical outcomes in AWS [52]A1b[81]A1b[85]A1b.
Psychopharmacology Monitoring and Safety Surveillance
- ▸Monitor for bradycardia when using alpha-adrenergic modulators [92].
- ▸Continuous telemetry is indicated for high-risk patients to detect self-terminating torsade [92].
AWS patients are at high risk for torsade de pointes due to electrolyte shifts and QT-prolonging drugs [92]C4. Serial ECGs are mandatory when using antipsychotics or in patients with liver disease. Concomitant (e.g., ) and vasoactive support (e.g., ) exacerbate QT prolongation [92]C4. Aggressive correction of hypokalaemia and hypomagnesemia is required [92]C4.
| ECG Finding | Significance |
|---|---|
| Prolonged QT | Risk for torsade de pointes [92]C4 |
| Sinus Bradycardia | Iatrogenic or autonomic exhaustion [92]C4 |
| Ventricular Premature Complexes | Warning for ventricular tachycardia [92]C4 |
Pearl: Hospitalized patients with AWS often have multiple silent risk factors for proarrhythmic responses; always review the medication profile for QT-prolonging drugs and correct even mild hypokalaemia immediately to prevent torsade de pointes [92]C4.
| Risk Factor | Clinical Consideration | Management Action |
|---|---|---|
| Hypokalaemia | Lowers ventricular arrhythmia threshold | Immediate replacement [92]C4 |
| QT-Prolonging Drugs | Antibiotics, antipsychotics, dopamine | Withdraw or substitute offending agents [92]C4 |
| Comorbidities | HIV, chronic liver disease, surgical stress | Increase frequency of ECG monitoring [92]C4 |
| Autonomic Surge | Agitation and withdrawal-related catecholamine release | Optimize AWS sedation protocol [92]C4 |
Risk and Safety Assessment, Capacity and Therapeutic Setting
- ▸AWS severely impairs decision-making capacity, often requiring involuntary care for DTs [95].
- ▸Surgical patients with AWS require intensive monitoring due to high secondary operative rates [95].
PAWSS score ≥4 (LR 174) is the primary safety metric [27]A1a. AUDIT-PC ≥4 is 91% sensitive for AWS development [8]B3b. In surgical settings (e.g., and neck reconstruction), AWS significantly lowers flap survival (83% vs 96.4%) and increases complications (52%) [95]B3b. Suicide risk is high; standard screenings in restrictive settings may miss 33-50% of at-risk detainees [96]B2b.
| Metric | AWS Group | Control | P-value |
|---|---|---|---|
| Flap Survival | 83% | 96.4% | <0.001 [95]B3b |
| Complications | 52% | Lower | <0.001 [95]B3b |
| Addtl. Surgery | 35.2% | Lower | <0.001 [95]B3b |
Pearl: A PAWSS score of 4 or higher is the most powerful predictor of severe withdrawal (LR 174), and its absence (score ≤3) virtually rules out the risk of delirium tremens or seizures [27]A1a.
| Tool | Threshold | Sensitivity | Specificity | Likelihood Ratio (LR+) |
|---|---|---|---|---|
| PAWSS | ≥4 points | 0.99 | 0.93 | 174 |
| AUDIT-PC | ≥4 points | 91.0% | 89.7% | N/A (AUC 0.95) |
| History of DTs | Presence | N/A | N/A | 2.9 |
| Systolic BP | ≥140 mmHg | N/A | N/A | 1.7 |
History and Evolution of Treatment
- ▸Symptom-triggered BZD protocols are now preferred over fixed-dose regimens [56].
- ▸Ethanol administration for withdrawal lacks high-quality evidence and may worsen outcomes [102].
Treatment has evolved from non-specific sedation to targeted modulation. became the standard in the 1980s [56]A1c. A 1989 trial showed outpatient detoxification with is cost-effective ($175-$388) for mild cases [100]A1b. Adding can reduce hospital stays by one day [99]A1b. (1200 mg/day) modulates GABA/glutamate and reduces heavy drinking days [97]A1b[44]A1c. has seen a clinical resurgence as a BZD adjunct [44]A1c[101]D5.
Pearl: The evolution of treatment has moved away from universal heavy sedation toward symptom-triggered benzodiazepine protocols and the early use of non-GABAergic adjuncts like or to reduce total burden and hospital length of stay [44]A1c[99]A1b[101]D5.
| Agent | Historical Role | Current Evidence/Status |
|---|---|---|
| Replacement for barbiturates | Gold standard; symptom-triggered dosing preferred [56]A1c | |
| Autonomic control | Reduces hospital stay by 1 day and lowers BDZ requirements [99]A1b | |
| Anticonvulsant | Reduces heavy drinking and withdrawal symptoms; modulates glutamate [44]A1c[97]A1b | |
| Early 20th-century primary | Resurging as an adjunct for severe/refractory cases [44]A1c[101]D5 | |
| Routine supplement | No significant benefit in CIWA-Ar score reduction [52]A1b | |
| Ethanol | Prophylaxis | Poor quality evidence; potential for worse outcomes [102]A1a |
Complications, Comorbidity and Iatrogenic Harm
- ▸Symptom-triggered BZD dosing reduces 90-day readmission rates (HR 2.61) [105].
- ▸[[Dexmedetomidine]] is associated with significantly longer hospital stays (10 vs 5 days) [69].
Severe withdrawal (SAWS) carries high mortality if untreated [27]A1a. In alcohol-associated hepatitis, AWS increases infections (OR 2.24) and mechanical ventilation needs (OR 2.49) [30]B2b. Iatrogenic risks include over-sedation from BZDs, which are associated with higher mortality in hepatitis patients (HR 2.18) [30]B2b. Chronic AUD-related hyperalgesia increases craving and relapse risk [29]D5.
| Complication | Predictor | Impact |
|---|---|---|
| Delirium Tremens | History of DT (LR 2.9) | High mortality [27]A1a |
| Seizures | Prior complicated AWS | Status epilepticus risk [89]D5 |
| Hyperalgesia | Chronic AUD | Relapse risk [29]D5 |
Pearl: A history of delirium tremens is the strongest individual clinical predictor for recurrence (LR 2.9), necessitating aggressive prophylaxis to prevent high-mortality outcomes [27]A1a[30]B2b.
| Predictor | Likelihood Ratio (LR) | 95% CI |
|---|---|---|
| PAWSS Score ≥ 4 | 174 | 43-696 |
| History of Delirium Tremens | 2.9 | 1.7-5.2 |
| Systolic BP ≥ 140 mm Hg | 1.7 | 1.3-2.3 |
| PAWSS Score ≤ 3 | 0.07 (Negative LR) | 0.02-0.26 |
Prognosis and Natural History
- ▸CIWA-Ar scores typically show significant decrease between days 1-3 and 4-9 [55].
- ▸Prophylaxis in high-risk patients reduces incident withdrawal risk (OR 0.58) [30].
Symptoms peak within 72 hours and resolve over one week [55]A1a. Approximately 3-5% of patients progress to DTs or convulsions [108]A1c. A Wetterling score >9 in the first 3 days is independently associated with increased mortality (OR 2.53) [58]B3b. AWS is also a risk factor for relapse after (sHR 5.89) [59]B3b.
| Wetterling Score | Mortality | Odds Ratio |
|---|---|---|
| Mild (<6) | 2.2% | Reference |
| Moderate (6-9) | 3.6% | N/A |
| Severe (>9) | 7.6% | 2.53 [58]B3b |
Pearl: A maximum withdrawal score >9 within the first 72 hours of admission is a critical threshold that more than doubles the risk of in-hospital mortality (OR 2.53) [58]B3b.
| Predictor | Outcome Impact | Statistical Significance |
|---|
Special Populations, Pregnancy and Perinatal Psychiatry
- ▸[[Phenobarbital]]'s protective effect on length of stay is strongest at low BZD doses (<3 mg) [114].
- ▸AUD patients with seizures have an 18% risk of co-occurring [[bacterial meningitis]] [48].
Geriatric patients have a higher threshold for admission [113]B3b. In surgical populations, AWS increases postoperative respiratory failure (aOR 2.44) [39]B2c. In trauma, adding to reduces intubation risk by 67% (OR 0.33) compared to [114]B3b. Pregnancy management lacks RCT data; anti-seizure medications are generally avoided as first-line due to adverse events (OR 1.86) [110]A1a[111]B3b.
Pearl: In medically complex or trauma patients, early use of over as a adjunct reduces the risk of unplanned intubation by 67% (OR 0.33) [114]B3b.
| Event Type | Adjusted Odds Ratio (aOR) | 95% Confidence Interval |
|---|---|---|
| Unplanned Intubation | 2.51 | Reported [112]B3b |
| Unplanned ICU Admission | 2.14 | Reported [112]B3b |
| Unplanned Trip to OR | 1.54 | Reported [112]B3b |
Prevention, Screening and Early Intervention
- ▸Symptom-triggered titration is the primary feature of improved outcomes in critical care [115].
- ▸Time since last drink and elevated SBP are strong predictors of SAWS risk [35].
Universal screening via PAWSS or FAST is essential [50]B2a[35]B3b. Risk factors for AWS development include age ≥45, male sex, and AST ≥40 U/L [31]B2b. (8 mg/day) is as effective as (80 mg/day) and is preferred in liver impairment [116]A1b. Outpatient detoxification is cost-effective for mild-to-moderate cases [72]B2a. (2500 mg/d) and (300 mg/d) are safe outpatient options [117]C4.
Pearl: Use the PAWSS or a combination of risk factors (age ≥45, male sex, and AST ≥40 U/L) to identify patients requiring prophylactic intervention before the onset of severe symptoms [31]B2b[50]B2a.
| Risk Condition | Association | Significance |
|---|
References
- [1]
Feeney C, Alter HJ, Jacobsen E et al.. “A Simplified Protocol for the Treatment of Alcohol Withdrawal.” Journal of addiction medicine (2015). PMID: 26501787 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [2]
Ng C, Fleury M, Hakmi H et al.. “The impact of alcohol use and withdrawal on trauma outcomes: A case control study.” American journal of surgery (2020). PMID: 33454025 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [3]
Steel TL, Malte CA, Bradley KA et al.. “Prevalence and Variation of Clinically Recognized Inpatient Alcohol Withdrawal Syndrome in the Veterans Health Administration.” Journal of addiction medicine (2020). PMID: 31609866 ↗
L2OTHERCited in: Definition, Classification and Nomenclature - [4]
Sanvisens A, Zuluaga P, Short A et al.. “Sex-specific Associations of Alcohol Withdrawal in Patients Admitted for the Treatment of Alcohol Use Disorder.” Journal of addiction medicine (Unknown). PMID: 32769772 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [5]
Steel TL, Malte CA, Bradley KA et al.. “Benzodiazepine Treatment and Hospital Course of Medical Inpatients With Alcohol Withdrawal Syndrome in the Veterans Health Administration.” Mayo Clinic proceedings. Innovations, quality & outcomes (2022). PMID: 35224452 ↗
L2OTHERCited in: Definition, Classification and Nomenclature - [6]
Melkonian A, Patel R, Magh A et al.. “Assessment of a Hospital-Wide CIWA-Ar Protocol for Management of Alcohol Withdrawal Syndrome.” Mayo Clinic proceedings. Innovations, quality & outcomes (2019). PMID: 31485573 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [7]
Heavner JJ, Akgün KM, Heavner MS et al.. “Implementation of an ICU-Specific Alcohol Withdrawal Syndrome Management Protocol Reduces the Need for Mechanical Ventilation.” Pharmacotherapy (2018). PMID: 29800507 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [8]
Pecoraro A, Ewen E, Horton T et al.. “Using the AUDIT-PC to predict alcohol withdrawal in hospitalized patients.” Journal of general internal medicine (2014). PMID: 23959745 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Risk and Safety Assessment, Capacity and Therapeutic Setting - [9]
Wong A, Benedict NJ, Kane-Gill SL. “Multicenter evaluation of pharmacologic management and outcomes associated with severe resistant alcohol withdrawal.” Journal of critical care (2014). PMID: 25433725 ↗
L3OTHERCited in: Definition, Classification and Nomenclature - [10]
Liu J, Wang LN. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2019). PMID: 31689723 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology - [11]
Liu J, Wang LN. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2017). PMID: 28822350 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology - [12]
Liu J, Wang LN. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2015). PMID: 25836263 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology - [13]
Liu J, Wang LN. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2013). PMID: 23450582 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Prevention, Screening and Early Intervention - [14]
Liu J, Wang L. “Baclofen for alcohol withdrawal.” The Cochrane database of systematic reviews (2011). PMID: 21249712 ↗
L1SR_OBSCited in: Neurobiology and Pathophysiology, Prevention, Screening and Early Intervention - [15]
Addolorato G, Leggio L, Abenavoli L et al.. “Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam.” The American journal of medicine (2006). PMID: 16490478 ↗
L1RCTCited in: Neurobiology and Pathophysiology - [16]
Bahji A, Crockford D, El-Guebaly N. “Neurobiology and Symptomatology of Post-Acute Alcohol Withdrawal: A Mixed-Studies Systematic Review.” Journal of studies on alcohol and drugs (2022). PMID: 35838422 ↗
L5SR_OBSCited in: Neurobiology and Pathophysiology, Acute Management and Psychiatric Emergencies - [17]
Huang MC, Chen CH, Pan CH et al.. “Lack of efficacy of dextromethorphan in managing alcohol withdrawal: a preliminary report of a randomized, double-blind, placebo-controlled trial.” Journal of clinical psychopharmacology (2014). PMID: 24346753 ↗
L1RCTCited in: Neurobiology and Pathophysiology, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [18]
Elsing C, Stremmel W, Grenda U et al.. “Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study.” The American journal of drug and alcohol abuse (2009). PMID: 19462303 ↗
L1RCTCited in: Neurobiology and Pathophysiology - [19]
Kähkönen S, Bondarenko B, Lipsanen J et al.. “Cardiovascular effects of propranolol in patients with alcohol dependence during withdrawal.” International journal of psychophysiology : official journal of the International Organization of Psychophysiology (2007). PMID: 17761330 ↗
L4TRIAL_NONRANDOMCited in: Neurobiology and Pathophysiology - [20]
Lokhande AV, Sadar SS, Vyawahare NS et al.. “Alcohol withdrawal and the sigma receptor: exploring the link between withdrawal and cognitive impairment.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 41094122 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [21]
Maldonado JR. “Novel Algorithms for the Prophylaxis and Management of Alcohol Withdrawal Syndromes-Beyond Benzodiazepines.” Critical care clinics (2017). PMID: 28601135 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [22]
Long D, Long B, Koyfman A. “The emergency medicine management of severe alcohol withdrawal.” The American journal of emergency medicine (2017). PMID: 28188055 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [23]
Brotherton AL, Hamilton EP, Kloss HG et al.. “Propofol for Treatment of Refractory Alcohol Withdrawal Syndrome: A Review of the Literature.” Pharmacotherapy (2016). PMID: 26893017 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [24]
Mirijello A, D'Angelo C, Ferrulli A et al.. “Identification and management of alcohol withdrawal syndrome.” Drugs (2015). PMID: 25666543 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [25]
Muzyk AJ, Kerns S, Brudney S et al.. “Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.” CNS drugs (2013). PMID: 23975661 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [26]
Carlson RW, Kumar NN, Wong-Mckinstry E et al.. “Alcohol withdrawal syndrome.” Critical care clinics (2012). PMID: 22998991 ↗
L5REVIEW_NARRATIVECited in: Neurobiology and Pathophysiology - [27]
Wood E, Albarqouni L, Tkachuk S et al.. “Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review.” JAMA (2018). PMID: 30167704 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Risk and Safety Assessment, Capacity and Therapeutic Setting, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm - [28]
Polintan ETT, Danganan LML, Cruz NS et al.. “Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials.” The Annals of pharmacotherapy (2022). PMID: 36258676 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology and Risk Factors - [29]
De Aquino JP, Sloan ME, Nunes JC et al.. “Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic.” The American journal of psychiatry (2024). PMID: 38706339 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm - [30]
Marti-Aguado D, Gougol A, Gomez-Medina C et al.. “Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study.” EClinicalMedicine (2023). PMID: 37415844 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm, Prognosis and Natural History - [31]
Marchand TD, Dunham CM, Chance EA et al.. “Trauma center admission risk conditions and the probability for developing alcohol withdrawal syndrome: A retrospective study.” Injury (2022). PMID: 36096958 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Prevention, Screening and Early Intervention - [32]
Rojo-Mira J, Pineda-Álvarez M, Zapata-Ospina JP. “Efficacy and Safety of Anticonvulsants for the Inpatient Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis.” Alcohol and alcoholism (Oxford, Oxfordshire) (2022). PMID: 34396386 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Course Specifiers and Risk Stratification - [33]
Sarkar PR, Edinoff AN, Suzuki J. “Unnecessary Use of Medications for Alcohol Withdrawal Among Hospitalized Patients: A Retrospective Study of Phosphatidylethanol Testing in Patients With Suspected Alcohol Use Disorder.” Journal of the Academy of Consultation-Liaison Psychiatry (2025). PMID: 39978639 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors - [34]
Cuperfain AB, Costa T, Chopra N. “Is Gastric Bypass a Risk Factor for Complicated Alcohol Withdrawal? Case Report and Literature Review.” Journal of addiction medicine (Unknown). PMID: 34049314 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation - [35]
Benson G, McCallum J, Roberts NJ. “Risk Factors for Severe Alcohol Withdrawal Syndrome in an Acute Hospital Population.” Journal of addictions nursing (2019). PMID: 31478963 ↗
L3RCTCited in: Epidemiology, Etiology and Risk Factors, Prevention, Screening and Early Intervention - [36]
Unlu H, Zhang N, Yehia A et al.. “Age and Sex Differences in Alcohol Withdrawal Syndrome.” Mayo Clinic proceedings. Innovations, quality & outcomes (2026). PMID: 42221909 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications, Comorbidity and Iatrogenic Harm - [37]
Liauw D, Regan S, Brodney S et al.. “Race, Ethnicity, and Language Differences in Inpatient Discharge Prescriptions for Alcohol Use Disorder at an Academic Medical Center.” Journal of general internal medicine (2026). PMID: 41606287 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [38]
Alkan G, Altin D, Yararbas G et al.. “Relationship between smoking and marital adjustment & social support among women with spouses experiencing alcohol/substance use disorders.” BMC women's health (2025). PMID: 40841890 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors - [39]
Sarfraz A, Mevawalla A, Altaf A et al.. “Nationwide Trends and Perioperative Outcomes of Alcohol Withdrawal Syndrome after Major Operation.” Journal of the American College of Surgeons (2025). PMID: 40693664 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry - [40]
Muto H, Kuzuya T, Tachi Y et al.. “Alcoholic Hepatitis in a Japanese Hospital: Losing Contact With Some Patients After Delirium Tremens May Lead to Missed Critical Events.” Addiction biology (2025). PMID: 40454635 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Special Populations, Pregnancy and Perinatal Psychiatry - [41]
Sarai M, Tejani AM, Chan AH et al.. “Magnesium for alcohol withdrawal.” The Cochrane database of systematic reviews (2013). PMID: 23740536 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Acute Management and Psychiatric Emergencies, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [42]
Minozzi S, Amato L, Vecchi S et al.. “Anticonvulsants for alcohol withdrawal.” The Cochrane database of systematic reviews (2010). PMID: 20238337 ↗
L1SR_OBSCited in: Clinical Presentation - [43]
Amato L, Minozzi S, Davoli M. “Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.” The Cochrane database of systematic reviews (2011). PMID: 21678378 ↗
L1SR_OBSCited in: Clinical Presentation - [44]
Borgundvaag B, Bellolio F, Miles I et al.. “Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2024). PMID: 38747203 ↗
L1GUIDELINECited in: Clinical Presentation, Acute Management and Psychiatric Emergencies, History and Evolution of Treatment - [45]
Mo Y, Thomas MC, Karras GE. “Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials.” Journal of critical care (2015). PMID: 26795441 ↗
L1TRIAL_NONRANDOMCited in: Clinical Presentation, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [46]
Pourmand A, AlRemeithi R, Kartiko S et al.. “Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis.” The American journal of emergency medicine (2023). PMID: 37060631 ↗
L1SR_OBSCited in: Clinical Presentation, Complications, Comorbidity and Iatrogenic Harm - [47]
Gallus S, Lugo A, Borroni E et al.. “Symptoms of Protracted Alcohol Withdrawal in Patients with Alcohol Use Disorder: A Comprehensive Systematic Review.” Current neuropharmacology (2023). PMID: 35794766 ↗
L1SR_OBSCited in: Clinical Presentation, Acute Management and Psychiatric Emergencies - [48]
van Veen KE, Brouwer MC, van der Ende A et al.. “Bacterial meningitis in alcoholic patients: A population-based prospective study.” The Journal of infection (2017). PMID: 28065808 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry - [49]
Caputo F, Skala K, Mirijello A et al.. “Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial.” CNS drugs (2014). PMID: 24996524 ↗
L1RCTCited in: Clinical Presentation - [50]
Maldonado JR, Sher Y, Ashouri JF et al.. “The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome.” Alcohol (Fayetteville, N.Y.) (2014). PMID: 24657098 ↗
L2SR_OBSCited in: Clinical Presentation, Risk and Safety Assessment, Capacity and Therapeutic Setting, Prevention, Screening and Early Intervention - [51]
Chen X, Yang C, Du C et al.. “Clinical analysis of alcoholic pellagra: A single-center retrospective study.” Journal of cosmetic dermatology (2022). PMID: 35500141 ↗
L4COHORTCited in: Clinical Presentation, Prognosis and Natural History - [52]
Airagnes G, Valter R, Ducoutumany G et al.. “Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial.” Alcohol and alcoholism (Oxford, Oxfordshire) (2023). PMID: 37012631 ↗
L1RCTCited in: Clinical Presentation, Severity, Course Specifiers and Risk Stratification, Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, History and Evolution of Treatment - [53]
Singal AK, Bataller R, Ahn J et al.. “ACG Clinical Guideline: Alcoholic Liver Disease.” The American journal of gastroenterology (2018). PMID: 29336434 ↗
L1GUIDELINECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out) - [54]
Holleck JL, Merchant N, Gunderson CG. “Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials.” Journal of general internal medicine (2019). PMID: 30937668 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out) - [55]
Pribék IK, Kovács I, Kádár BK et al.. “Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol - Revised: A systematic review-based meta-analysis.” Drug and alcohol dependence (2021). PMID: 33503582 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Severity, Course Specifiers and Risk Stratification, Prognosis and Natural History - [56]
Mierzejewski P, Bieńkowski P, Jakubczyk A et al.. “Pharmacotherapy of alcohol withdrawal syndromes - Recommendations of the Polish Psychiatric Association and the Pharmacotherapy Section of the Polish Society for Addiction Research.” Psychiatria polska (2022). PMID: 36342978 ↗
L1GUIDELINECited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), History and Evolution of Treatment - [57]
Qu L, Ma XP, Simayi A et al.. “Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis.” International clinical psychopharmacology (2023). PMID: 38170803 ↗
L1SR_OBSCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History - [58]
Griessbach AN, Mueller BU, Battegay E et al.. “The maximum alcohol withdrawal syndrome score associates with worse clinical outcomes-A retrospective cohort study.” Drug and alcohol dependence (2019). PMID: 31715439 ↗
L3COHORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History - [59]
Attilia ML, Lattanzi B, Ledda R et al.. “The multidisciplinary support in preventing alcohol relapse after liver transplantation: A single-center experience.” Clinical transplantation (2018). PMID: 29573476 ↗
L3TRIAL_NONRANDOMCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History - [60]
Song Y, Xue X, Han H et al.. “Efficacy of transcutaneous electrical acupoint stimulation combined with diazepam for acute alcohol withdrawal syndrome: A double-blind randomized sham-controlled trial.” The Journal of international medical research (2020). PMID: 32340502 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Prognosis and Natural History - [61]
Volchegorskii IA, Izarovskii BV, Shamaeva TN et al.. “[An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021). PMID: 34693691 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out) - [62]
Melby K, Fasmer OB, Henriksen TE et al.. “Actigraphy assessment of motor activity and sleep in patients with alcohol withdrawal syndrome and the effects of intranasal oxytocin.” PloS one (2020). PMID: 32053696 ↗
L1RCTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Special Populations, Pregnancy and Perinatal Psychiatry - [63]
Nelson CA, Murua C, Jones JM et al.. “Francisella tularensis Transmission by Solid Organ Transplantation, 20171.” Emerging infectious diseases (2019). PMID: 30730826 ↗
L4CASE_REPORTCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out) - [64]
Wolpaw BJ, Oren H, Quinnan-Hostein L et al.. “Hospital-Wide Implementation, Clinical Outcomes, and Safety of Phenobarbital for Alcohol Withdrawal.” JAMA network open (2025). PMID: 40853658 ↗
L3OTHERCited in: Diagnosis and Workup (Criteria, Rating Scales and Organic Rule-Out), Special Populations, Pregnancy and Perinatal Psychiatry - [65]
Ganatra RB, Breu AC, Ronan MV. “Clinical guideline highlights for the hospitalist: 2020 American Society of Addiction Medicine clinical practice guideline on alcohol withdrawal management.” Journal of hospital medicine (2022). PMID: 34910619 ↗
L1GUIDELINECited in: Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment - [66]
Nishimura Y, Choi H, Colgan B et al.. “Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome.” European journal of internal medicine (2023). PMID: 36935249 ↗
L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification, Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm - [67]
Bachoumas K, Levrat A, Le Thuaut A et al.. “Epidural analgesia in ICU chest trauma patients with fractured ribs: retrospective study of pain control and intubation requirements.” Annals of intensive care (2020). PMID: 32852675 ↗
L3COHORTCited in: Severity, Course Specifiers and Risk Stratification - [68]
Ghosh A, Mahintamani T, Choudhury S et al.. “The Effectiveness of Non-Benzodiazepine, Non-Barbiturate Medications for Alcohol Withdrawal Syndrome: A Rapid Systematic Review.” Alcohol and alcoholism (Oxford, Oxfordshire) (2021). PMID: 33264386 ↗
L2SR_OBSCited in: Severity, Course Specifiers and Risk Stratification - [69]
Ashok A, Sharma R, Ahmed S et al.. “Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study.” Journal of clinical medicine research (2025). PMID: 41367828 ↗
L3COHORTCited in: Severity, Course Specifiers and Risk Stratification, Complications, Comorbidity and Iatrogenic Harm - [70]
DeFoster RE, Morgan RJ, Leung JG et al.. “Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial.” Substance use & misuse (2023). PMID: 37469099 ↗
L2RCTCited in: Severity, Course Specifiers and Risk Stratification, History and Evolution of Treatment, Complications, Comorbidity and Iatrogenic Harm - [71]
Fluyau D, Kailasam VK, Pierre CG. “Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management.” European journal of clinical pharmacology (2023). PMID: 37380897 ↗
L1SR_OBSCited in: Severity, Course Specifiers and Risk Stratification - [72]
Quelch D, Granger R, Lloyd-Williams H et al.. “A systematic review of the economic evidence surrounding the management of alcohol withdrawal.” Drug and alcohol review (2025). PMID: 40223455 ↗
L2SR_OBSCited in: Acute Management and Psychiatric Emergencies, Prevention, Screening and Early Intervention - [73]
Lee CM, Dillon DG, Tahir PM et al.. “Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2024). PMID: 37923363 ↗
L1SR_OBSCited in: Acute Management and Psychiatric Emergencies - [74]
Punia K, Scott W, Manuja K et al.. “SAEM GRACE: Phenobarbital for alcohol withdrawal management in the emergency department: A systematic review of direct evidence.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2023). PMID: 37589203 ↗
L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm - [75]
Mattle AG, McGrath P, Sanu A et al.. “Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.” Drug and alcohol dependence (2022). PMID: 36402053 ↗
L1SR_OBSCited in: Acute Management and Psychiatric Emergencies, Complications, Comorbidity and Iatrogenic Harm - [76]
Treiber MC, Grünberger J, Vyssoki B et al.. “Pupillary response to percutaneous auricular vagus nerve stimulation in alcohol withdrawal syndrome: A pilot trial.” Alcohol (Fayetteville, N.Y.) (2023). PMID: 37661002 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Psychiatric Emergencies - [77]
Crunelle CL, Jegham S, Vanderbruggen N et al.. “Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial.” Alcohol and alcoholism (Oxford, Oxfordshire) (2023). PMID: 37526038 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies, History and Evolution of Treatment - [78]
Williams J, Collins L, Norman A et al.. “A Placebo-Controlled Randomized Trial of Vigabatrin in the Management of Acute Alcohol Withdrawal.” Alcohol and alcoholism (Oxford, Oxfordshire) (2023). PMID: 36161306 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies, History and Evolution of Treatment, Prognosis and Natural History - [79]
Filewod N, Hwang S, Turner CJ et al.. “Phenobarbital for the management of severe acute alcohol withdrawal (the PHENOMANAL trial): a pilot randomized controlled trial.” Pilot and feasibility studies (2022). PMID: 35065662 ↗
L1RCTCited in: Acute Management and Psychiatric Emergencies - [80]
Latifi S, Messer T. “The Efficacy of Tiapride and Carbamazepine Combination Therapy in Reducing Alcohol Withdrawal Symptoms: A Systematic Review and Meta-Analysis.” Pharmacopsychiatry (2018). PMID: 30522144 ↗
L1SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [81]
Melby K, Gråwe RW, Aamo TO et al.. “Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial.” Drug and alcohol dependence (2019). PMID: 30784955 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Prognosis and Natural History - [82]
Maldonado JR, Nguyen LH, Schader EM et al.. “Benzodiazepine loading versus symptom-triggered treatment of alcohol withdrawal: a prospective, randomized clinical trial.” General hospital psychiatry (2012). PMID: 22898443 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [83]
Addolorato G, Lesch OM, Maremmani I et al.. “Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects.” Expert opinion on drug safety (2019). PMID: 31876433 ↗
L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [84]
Fullwood JE, Mostaghimi Z, Granger CB et al.. “Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study.” American journal of critical care : an official publication, American Association of Critical-Care Nurses (2013). PMID: 23996419 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [85]
Rosenson J, Clements C, Simon B et al.. “Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study.” The Journal of emergency medicine (2012). PMID: 22999778 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [86]
Förg A, Hein J, Volkmar K et al.. “Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial.” Alcohol and alcoholism (Oxford, Oxfordshire) (2012). PMID: 22215002 ↗
L1RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [87]
VanderWeide LA, Foster CJ, MacLaren R et al.. “Evaluation of Early Dexmedetomidine Addition to the Standard of Care for Severe Alcohol Withdrawal in the ICU: A Retrospective Controlled Cohort Study.” Journal of intensive care medicine (2014). PMID: 25326428 ↗
L3COHORTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [88]
Reddy VK, Girish K, Lakshmi P et al.. “Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome.” Indian journal of pharmacology (2014). PMID: 25097273 ↗
L2RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [89]
Faustmann TJ, Paschali M, Kojda G et al.. “[Antipsychotic Treatment of Alcohol Withdrawal Syndrome with Focus on Delirium Tremens: a Systematic Review].” Fortschritte der Neurologie-Psychiatrie (2023). PMID: 36958342 ↗
L5SR_OBSCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies, Complications, Comorbidity and Iatrogenic Harm - [90]
Hamilton E, Bouchard B. “The Use of Oral Phenobarbital Loading for the Management of Alcohol Withdrawal Syndrome in an Outpatient Setting: A Case Report.” Journal of addiction medicine (2024). PMID: 39621554 ↗
L4CASE_REPORTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [91]
Agibalova TV, Buzik OZ, Rychkova OV et al.. “[Alcohol withdrawal syndrome dynamics during treatment with nooclerin (deanoli aceglumas)].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2018). PMID: 29658504 ↗
L2RCTCited in: Long-Term and Definitive Management: Psychotherapy, Pharmacotherapy and Somatic/Neuromodulation Therapies - [92]
Panduranga P, Al-Mukhaini M, Rajarao MP. “Multi-factorial causes of torsade de pointes in a hospitalised surgical patient.” Sultan Qaboos University medical journal (2013). PMID: 23573398 ↗
L4OTHERCited in: Psychopharmacology Monitoring and Safety Surveillance - [93]
Burkhardt G, Adorjan K, Kambeitz J et al.. “A machine learning approach to risk assessment for alcohol withdrawal syndrome.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2020). PMID: 32418843 ↗
L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting - [94]
Guglielmo R, Martinotti G, Clerici M et al.. “Pregabalin for alcohol dependence: a critical review of the literature.” Advances in therapy (2012). PMID: 23132700 ↗
L5REVIEW_NARRATIVECited in: Risk and Safety Assessment, Capacity and Therapeutic Setting - [95]
Kuo YR, Jeng SF, Lin KM et al.. “Microsurgical tissue transfers for head and neck reconstruction in patients with alcohol-induced mental disorder.” Annals of surgical oncology (2007). PMID: 17973172 ↗
L3OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting - [96]
McKinnon IG, Grubin D. “Health screening of people in police custody--evaluation of current police screening procedures in London, UK.” European journal of public health (2012). PMID: 22539630 ↗
L2OTHERCited in: Risk and Safety Assessment, Capacity and Therapeutic Setting - [97]
Prisciandaro JJ, Hoffman M, Brown TR et al.. “Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial.” The American journal of psychiatry (2021). PMID: 34256607 ↗
L1RCTCited in: History and Evolution of Treatment - [98]
Gallimberti L, Canton G, Gentile N et al.. “Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.” Lancet (London, England) (1989). PMID: 2571021 ↗
L1RCTCited in: History and Evolution of Treatment - [99]
Kraus ML, Gottlieb LD, Horwitz RI et al.. “Randomized clinical trial of atenolol in patients with alcohol withdrawal.” The New England journal of medicine (1985). PMID: 2863754 ↗
L1RCTCited in: History and Evolution of Treatment - [100]
Hayashida M, Alterman AI, McLellan AT et al.. “Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome.” The New England journal of medicine (1989). PMID: 2913493 ↗
L1RCTCited in: History and Evolution of Treatment - [101]
Abrams TE, Ronan MV. “Clinical progress note: Phenobarbital in the treatment of alcohol withdrawal syndrome.” Journal of hospital medicine (2025). PMID: 40443022 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [102]
Quelch D, Davies N, McFauld C et al.. “Ethanol for the management of alcohol withdrawal syndrome: a systematic review.” Clinical toxicology (Philadelphia, Pa.) (2024). PMID: 39559850 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [103]
Vansteene C, Dubertret C, Aubin HJ et al.. “Severe alcohol withdrawal symptoms and the risk of suicidal acts in patients treated for alcohol use disorder.” The British journal of psychiatry : the journal of mental science (2025). PMID: 40977395 ↗
L2OTHERCited in: History and Evolution of Treatment - [104]
Ronan MV, Ganatra RB, Saukkonen J. “Establishing the safety of phenobarbital treatment of alcohol withdrawal syndrome on general medical wards: A retrospective cohort study.” Alcohol (Fayetteville, N.Y.) (2023). PMID: 37979844 ↗
L3COHORTCited in: Complications, Comorbidity and Iatrogenic Harm - [105]
Al-Maqbali JS, Al Alawi AM, Al-Mamari Q et al.. “Symptoms-triggered approach versus fixed-scheduled approach of benzodiazepines for management of alcohol withdrawal syndrome: Non-randomized controlled trial.” Alcohol (Fayetteville, N.Y.) (2022). PMID: 36240945 ↗
L2RCTCited in: Complications, Comorbidity and Iatrogenic Harm - [106]
Messinger JC, Hakimi E, Vercollone L. “The Use of a Single Dose of Phenobarbital for Inpatient Management of Benzodiazepine Withdrawal: A Case Report.” Journal of addiction medicine (2022). PMID: 36094077 ↗
L4CASE_REPORTCited in: Complications, Comorbidity and Iatrogenic Harm - [107]
Girish K, Vikram Reddy K, Pandit LV et al.. “A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome.” Biomedical journal (2016). PMID: 27105601 ↗
L1RCTCited in: Prognosis and Natural History - [108]
Caputo F, Agabio R, Vignoli T et al.. “Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol.” Internal and emergency medicine (2018). PMID: 30187438 ↗
L1GUIDELINECited in: Prognosis and Natural History - [109]
Woods AD, Giometti R, Weeks SM. “The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review.” JBI database of systematic reviews and implementation reports (2015). PMID: 26447017 ↗
L1SR_OBSCited in: Prognosis and Natural History - [110]
Lai JY, Kalk N, Roberts E. “The effectiveness and tolerability of anti-seizure medication in alcohol withdrawal syndrome: a systematic review, meta-analysis and GRADE of the evidence.” Addiction (Abingdon, England) (2021). PMID: 33822427 ↗
L1SR_OBSCited in: Special Populations, Pregnancy and Perinatal Psychiatry - [111]
Erfle BA, Steel TL, Law AC et al.. “Pharmacological Interventions for Alcohol Withdrawal Syndrome Among Hospitalized Adults: A Multicenter Cohort Study.” Journal of general internal medicine (2025). PMID: 40877712 ↗
L3COHORTCited in: Special Populations, Pregnancy and Perinatal Psychiatry - [112]
Buhrke K, Cucher D, Kovacs M. “Alcohol Use is Associated with Unplanned Hospital Events in Trauma Patients.” The Journal of surgical research (2026). PMID: 41734448 ↗
L3OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry - [113]
Briggs B, Smith L, Yates N et al.. “Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2025). PMID: 41147831 ↗
L3OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry - [114]
Matecki M, Noureldin A, Akkari R et al.. “Phenobarbital Addition to Alcohol Withdrawal Treatment Offers Better Outcomes than Dexmedetomidine in Hospitalized Patients.” Journal of intensive care medicine (2025). PMID: 40152196 ↗
L3OTHERCited in: Special Populations, Pregnancy and Perinatal Psychiatry - [115]
Awissi DK, Lebrun G, Coursin DB et al.. “Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary.” Intensive care medicine (2012). PMID: 23184039 ↗
L1SR_OBSCited in: Prevention, Screening and Early Intervention - [116]
Kumar CN, Andrade C, Murthy P. “A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal.” Journal of studies on alcohol and drugs (2009). PMID: 19371497 ↗
L1RCTCited in: Prevention, Screening and Early Intervention - [117]
Müller CA, Schäfer M, Banas R et al.. “A combination of levetiracetam and tiapride for outpatient alcohol detoxification: a case series.” Journal of addiction medicine (2011). PMID: 21769061 ↗
L4CASE_REPORTCited in: Prevention, Screening and Early Intervention - [118]
McKeon A, Frye MA, Delanty N. “The alcohol withdrawal syndrome.” Journal of neurology, neurosurgery, and psychiatry (2007). PMID: 17986499 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening and Early Intervention